Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,496.00-0.54%ETH$2,695.79-0.76%GOLD$4,194.70+0.18%OIL$89.85+0.46%
Smart Investors Daily
SID Premium
CT

NASDAQ · CTSO

Cytosorbents Corp.

Healthcare · Medical - Devices

$3.97

Down-$0.01 (-0.13%)

Updated Oct 6, 2026, 8:46 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.22M
P/E ratio
-4.27
Dividend yield
0.00%
52-week range
$0.30 – $9.43
Volume
8.38K
Avg. volume
95.06K

Price performance · CTSO

CTSO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

CTSO closed at $3.97 after 20 trading sessions, down 42.12% for the selected period.

Last close
$3.97
Period change
-42.12%
Period low
$3.90
Period high
$6.85
Daily close
View OHLC price history
CTSO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$3.85$4.05$3.66$3.9658.38K
Oct 2, 2026$4.17$4.29$3.83$4.0512.55K
Oct 1, 2026$4.38$4.50$3.93$4.1858.27K
Sep 30, 2026$4.13$4.15$3.765$3.9013.67K
Sep 29, 2026$4.08$4.48$4.00$4.009.81K
Sep 28, 2026$4.28$4.565$3.97$4.0214.26K
Sep 25, 2026$4.44$4.8275$4.33$4.386.53K
Sep 24, 2026$5.20$5.20$3.94$4.3024.87K
Sep 23, 2026$5.25$5.36$4.895$4.916.11K
Sep 22, 2026$5.53$5.59$5.31$5.326.35K
Sep 21, 2026$5.79$5.79$5.16$5.5114.27K
Sep 18, 2026$5.88$6.00$5.50$5.7511.77K
Sep 17, 2026$5.96$5.96$5.7501$5.763.07K
Sep 16, 2026$6.03$6.11$5.56$5.734.91K
Sep 15, 2026$6.00$6.2388$6.00$6.0612K
Sep 14, 2026$6.33$6.3436$5.13$6.06999.36K
Sep 11, 2026$6.50$6.615$6.32$6.4112.09K
Sep 10, 2026$6.37$6.74$6.25$6.3714.39K
Sep 9, 2026$6.74$6.98$6.11$6.3336.92K
Sep 8, 2026$6.76$7.44$6.75$6.8518.13K

Latest CTSO news

The latest Smart Investors Daily articles mentioning CTSO.

Stock researchCompany · Overview

CTSO research

Overview

Company profile and research snapshot.

Company profile

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CTSO recent ratings
DateFirmRatingTarget
Mar 26, 2026D. Boral CapitalBuy—
Jan 12, 2026D. Boral CapitalBuy—
Dec 16, 2025D. Boral CapitalBuy—
Nov 14, 2025D. Boral CapitalBuy—
Nov 14, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October 7-10, 2026 and in critical care at the European Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon, Portugal from October 1

Yahoo · Sep 23, 2026

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share.

Benzinga · Sep 23, 2026

CytoSorbents Regains Nasdaq Compliance

CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with

Yahoo · Sep 10, 2026

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14–16, 2026, in New York City. Dr. Phillip Chan, Chief Executive Officer and Peter Mariani, Chief Financial Officer of CytoSorbents will be attending the conference, joining Sean Lee, Vice Pr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By